IKATP blockers like the anti-diabetic drug glibenclamide or the more cardiac specific IKATP blocker HMR1883 have been found to effectively inhibit ventricular tachycardia after myocardial infarction in animal models (Dhein et al., 2000; Wirth et al., 2000). This evidence concerns the gene KCNJ11 and ventricular tachycardia.